Company Overview of ADC Therapeutics SA
ADC Therapeutics SA develops proprietary antibody drug conjugates (ADCs) for the treatment of solid and hematological cancers. It develops ADCT-301, an ADC for the treatment of CD25-expressing lymphoma and leukemia; and ADCT-402, a humanized antibody for the treatment of CD19-expressing non-Hodgkin’s lymphoma and B-cell leukemia. The company was founded in 2011 and is headquartered in Epalinges, Switzerland with research and laboratories in London, United Kingdom.
Route de la Corniche 3B
Founded in 2011
Key Executives for ADC Therapeutics SA
Chief Executive Officer and Director
Vice Chairman and Executive Vice President
Senior Vice President of Research & Development
Chief Medical Officer, Head of Oncology Clinical Development and Senior Vice President
Compensation as of Fiscal Year 2016.
ADC Therapeutics SA Key Developments
ADC Therapeutics Announces First Patient in Phase I Trial of ADCT-402 in CD-19 Positive B-Cell Non-Hodgkin Lymphomas
Mar 11 16
ADC Therapeutics announced that the first patient has been dosed in a Phase I trial to evaluate its antibody drug conjugate (ADC) ADCT-402 in B-cell non-Hodgkin Lymphoma (B-NHL). The two stage, open-label trial will evaluate the tolerability, safety, pharmacokinetics and activity of ADCT-402 in patients with relapsed or refractory B-NHL. The first stage is a dose escalation phase which will recruit up to 30 patients at ten clinical sites across the US and EU and will seek to determine the recommended dose of ADCT-402 for the second stage. The second stage, which will begin once an appropriate dose is identified, aims to confirm the safety and efficacy profile at the selected dose. ADCT-402 combines a humanized monoclonal antibody targeting the protein CD19 with a pyrrolo-benzodiazepine (PBD) warhead. CD19 is a B-cell specific surface protein expressed throughout B-cell development. It is expressed on nearly all B-cell malignancies in many non-Hodgkin lymphomas. Due to its specificity, it has become an attractive target for ADC therapies. In preclinical in vivo models, ADCT-402 exhibited strong dose-dependent anti-tumor activity against CD19-positive leukemic and lymphoma cell lines at low single doses, and it outperformed other CD19 targeted ADCs currently in clinical development. B-cell non-Hodgkin Lymphoma is a common type of non-Hodgkin lymphoma, a cancer of the lymphatic system. Non-Hodgkin Lymphomas overall are the 10th most common cancer in the world. In 2012, there were nearly 386,000 new cases diagnosed globally, with highest incidence rates reported in Northern America.
ADC Therapeutics Sarl Presents at BIO-Europe 2015, Nov-02-2015
Oct 1 15
ADC Therapeutics Sarl Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
ADC Therapeutics Announces Board Changes
Sep 28 15
ADC Therapeutics announced that Dr. Hans-Peter Wild and Jacques Theurillat have been appointed to its board of directors as non-executive directors. Dr. Wild is the owner and Chairman of the Wild Group and has built multiple global businesses, including Wild Flavours GmbH. As an independent non executive director, Mr. Theurillat brings to the Board extensive experience in strategy development, finance and commercial operations. He has been CEO of Ares Life Sciences AG and previously served as CEO and Chairman of Albea Pharmaceuticals AG. He also had an extensive career at Serono, which spanned roles such as Chief Financial Officer, Deputy Chief Executive Officer and Senior Executive Vice President, Strategic Corporate Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries